RxDoctor Payments Data

Janelle Grossman

Pain Medicine · Greensboro, NCNPI 1407190135

Payments from drug & device makers

$1,983in general payments, 2019–2025

Across 96 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$405
  • Boston Scientific$200
  • Forte Bio-pharma LLC$176
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$169
  • Lilly USA, LLC$146
  • Indivior Inc.$145
  • plus $741 from 23 others

What the payments were for

  • Food & beverage$1,983100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,983 in reported general payments places this provider in the 35th percentile of 182 pain medicine providers in North Carolina.

See all pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$40,936
Medicare patients
55
Services billed
801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen486$79,020
BelbucaBuprenorphine Hcl65$58,277
Xtampza ErOxycodone Myristate52$29,684
LinzessLinaclotide32$18,254
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen589$16,216
Buprenorphine66$16,169
Oxycodone Hcl481$7,879
Naloxone Hcl93$6,211
Gabapentin389$4,462
Fentanyl16$4,206
Baclofen352$3,011
Lidocaine23$2,167
Pregabalin116$1,582
Morphine Sulfate ErMorphine Sulfate64$1,541
Diclofenac Sodium56$1,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$405$87,960117 claims
AbbVieLinzess$46$18,25432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 182 pain medicine providers in North Carolina.

Other pain medicine in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →